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Abstract 
Aim:  Recently we have observed differences in the ability of metformin and AICAR 
to repress glucose production from hepatocytes using 8CPT-cAMP. Previous results 
indicate that besides activating protein kinase A, 8CPT-modified cAMP analogues 
suppress the Nitrobenzylthioinosine (NBMPR)-sensitive equilibrative nucleoside 
transporter ENT1.  We aimed to exploit 8CPT-cAMP, 8CPT-2-Methyl-O-cAMP and 
NBMPR, which is highly selective for a high-affinity binding-site on ENT1, to 
investigate the role of ENT1 in the liver specific glucose lowering properties of 
AICAR and metformin. 
Methods: Primary mouse hepatocytes were incubated with AICAR and metformin in 
combination with cAMP analogues, glucagon, forskolin and NBMPR. Hepatocyte 
glucose production (HGP), and AMPK signalling were measured and a uridine 
uptake assay with supporting LC-MS was used to investigate nucleoside depletion 
from medium by cells. 
Results: AICAR and metformin increased AMPK pathway phosphorylation and 
decreased HGP induced by dibutyryl cAMP and glucagon. HGP was also induced by 
8CPT-cAMP, 8CPT-2-Methyl-O-cAMP and NBMPR; however, in each case this was 
resistant to suppression by AICAR but not metformin. Cross-validation of tracer and 
mass spectrometry studies indicates that 8CPT-cAMP, 8CPT-2-Methyl-O-cAMP and 
NBMPR inhibited the effects of AICAR at least in part by impeding its uptake into 
hepatocytes.  
Conclusions: We report for the first time that suppression of ENT1 induces HGP. 
ENT1 inhibition also impedes uptake and effects of AICAR but not metformin on 
HGP. Further investigation of nucleoside transport may illuminate a better 
understanding of how metformin and AICAR each regulate HGP.  
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Introduction 
Stimuli that raise cyclic adenosine monophosphate (cAMP) levels in hepatocytes, 
including glucagon, induce de novo glucose production through gluconeogenesis 
and from glycogenolysis (1). Hyperglucagonaemia contributes to chronic 
hyperglycaemia observed in type 1 (T1D) and type 2 diabetes (T2D), through poorly 
defined mechanisms. Raised intracellular cAMP activates downstream effectors 
including cAMP-dependent protein kinase (PKA) (1; 2) to control gluconeogenic flux 
through the actions of PKA on fructose-1,6-bisphosphatase. Phosphorylation of 
cAMP-response element binding protein (CREB) by PKA is believed to contribute 
towards gluconeogenesis through increased expression of phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6-Pase). 
The hyperglycaemic effect of the glucagon/cAMP/PKA signalling pathway on liver 
cells has been studied using a number of different cAMP analogues, in combination 
with dexamethasone, to stimulate cAMP/PKA (3-5). Commonly used is the cAMP 
analogue dibutyryl cAMP (bucladesine, db-cAMP), a cell permeable stabilised cAMP 
mimic which also inhibits phosphodiesterase (PDE) activity (6; 7). Treatment of cells 
with db-cAMP causes a significant stimulation of PEPCK and G6-Pase expression, 
which is inhibited by the addition of insulin in a dose-dependent manner (8-10). 8-(4-
Chlorophenylthio)cAMP (8CPT-cAMP), like db-cAMP, is a membrane permeable 
cAMP analogue that stimulates PEPCK and G-6-Pase (4; 11); tends to be more 
potent than cAMP; is more resistant to phosphodiesterase-dependent hydrolysis and 
it acts as a PDE inhibitor (12).  
Studies using cAMP analogues have previously shown that the type 2 diabetes drug 
metformin and 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) repress 
cAMP-stimulated hepatocyte glucose production (HGP) (13-15). Inside cells, AICAR 
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is phosphorylated by adenosine kinase to form ZMP, which then acts as mimic of 
AMP to activate AMPK (16). Metformin and AICAR are both activators of AMPK; 
however earlier studies including some carried out in mice where the catalytic 
subunits of AMPK are genetically ablated, demonstrated that suppression of HGP 
occurs independently of AMPK activation (13-15; 17; 18).  Metformin is transported 
across hepatocyte cell membranes, at least in part, by organic cation transporter 
(OCT) family of transporters (18-20). Previous studies using siRNA determined that 
AICAR is transported by ENT1 and CNT3 into human macrophages (21), whereas 
AICAR uptake into hepatocytes and the role on HGP is less clear. Initiating the 
current investigation, we observed that HGP was highly resistant to inhibition by 
AICAR only when 8CPT-modified cAMP analogues were used to stimulate HGP. In 
contrast, repression of HGP by metformin was unaffected. 8CPT-modified cAMP 
analogues have previously been shown to inhibit the equilibrative nucleoside 
transporter (ENT1), which is expressed in the liver (22) and transports nucleosides 
across the plasma membrane depending upon the nucleoside concentration gradient 
(23). The inhibitory effect of 8CPT-modified cAMP analogues on AICAR action 
prompted us to investigate the role of ENT1 in metformin and AICAR-induced 
regulation of HGP using NBMPR, a highly selective ENT1 inhibitor (24). Our study 
indicates that suppression of ENT1 activity is sufficient to induce HGP. Moreover, the 
effects of AICAR but not metformin on HGP are sensitive to ENT1 inhibition. These 
data highlight direct and indirect roles for ENT1 in modulating HGP. 
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Materials and methods 
Materials  
AICAR and 4-Nitrobenzylthioinosine (NBMPR) were purchased from Tocris, dibutyryl 
cAMP, uridine and metformin were from Sigma (Dorset, UK). LC-MS materials were 
obtained from Fisher Scientific unless otherwise stated.  Glucagon was from Novo 
Nordisk (Bagsvaerd, Denmark).  8CPT-cAMP was purchased from Calbiochem and 
8CPT-2-Methyl-O-cAMP (8CPT-2MeO-cAMP) was from Biolog Life Sciences 
Institute (Bremen, Germany).  Donkey anti-goat 680RD, donkey anti-mouse 680RD, 
donkey anti-rabbit 800CW secondary antibodies were purchased from LI-COR 
Biosciences, UK.  GAGO glucose oxidase kit was purchased from Sigma. [5,6-3H] 
Uridine was purchased from Perkin Elmer.  pAMPK (Thr172) and total ACC 
antibodies were from Cell Signalling Technologies.  Total AMPK was purchased from 
Abcam, actin was from Proteintech and pACC was made in-house by DSTT 
(University of Dundee). 
 
Isolation of mouse primary hepatocytes 
Hepatocytes were isolated from adult female mice essentially as described by Foretz 
et al (14) and in accordance with the Animals (Scientific Procedures) Act 1986.  
Following successful isolation, cell viability was determined by 0.04% Trypan blue 
staining and the cell number determined using a haemocytometer.  Cell viability of 
>90% was required before experimental use.  Cells were plated at a density of 
2.5x105 cells per ml for all experiments. 
 
Measurement of Hepatocyte glucose production (HGP) from primary cells 
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HGP was measured essentially as previously described (25) using mouse primary 
hepatocytes. Viable cells were allowed to settle for 4-6 hours before serum 
starvation in M199 media containing dexamethasone (100 nM).  After overnight 
serum free conditions, cells were washed once in PBS before incubation for 8 hours 
in glucose free DMEM (Invitrogen) containing lactate (10 mM), pyruvate (1 mM), 
dexamethasone (100 nM) plus stimuli as indicated on the figure legends.  Media was 
harvested for measurement of glucose and hepatocytes were lysed. The amount of 
glucose present in the media was measured using GAGO glucose oxidase kit 
(Sigma). Glucose assays were performed in a 96-well plate format.  50 µl of cell 
culture media was incubated with 100 µl of glucose oxidase/peroxidase assay 
reagent for 30 minutes at 37oC before the reaction was stopped by the addition of 
100 µl 12N H2SO4.  Absorbance was measured at 405 nm and the amount of 
glucose present was determined using a glucose standard curve generated in the 
same assay.  The final glucose concentration was normalized to total protein content 
per well and data is presented as µg HGP per µg protein. 
 
Cell lysis and Western blotting 
Cells were lysed in buffer containing  Tris-HCl (50 mM; pH7.4), NaF (50 mM), 
sodium pyrophosphate (1 mM), EDTA (1 mM), EGTA (1 mM), NaCl (50 mM), 
sucrose (0.27 M), 1% (v/v) Triton-X100, 0.1% (v/v) 2-mercaptoethanol, sodium 
orthovanadate (1 mM), benzamidine (1mM) and 0.1% (v/v) pefabloc (a serine 
protease inhibitor).  Cells were allowed to lyse on ice for 30 minutes before scraping. 
Lysates were centrifuged at 13K rpm for 15 minutes at, 4̊C and prepared in 1x LDS 
(final) plus DTT (10 mM).  Gels were run at 150V for 90 minutes and transferred onto 
nitrocellulose (GE healthcare) for 3 hours at 75V before blocking in 1% (w/v) BSA, 
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TBS-T for 30 minutes at room temperature. Membranes were incubated with primary 
antibodies diluted 1:1000 except actin, which was diluted 1:5000 as indicated in the 
figure legends at 4°C overnight with shaking before washing 3x10 minutes in 1xTBS-
T. Secondary antibodies (LI-COR Biosciences, UK) were added at 1:5000 for 1 hour 
at room temperature with shaking. Protein bands were visualized using LI-COR 
Odyssey infra-red imaging system.  
 
Uridine Uptake Assay 
Primary mouse hepatocytes were incubated overnight in M199 media as described 
above.  Cells were washed once in uridine uptake buffer (20 mM Tris-HCl, 3 mM 
KH2PO4, 1 mM MgCl2.6H2O, 2 mM CaCl2, 5 mM Glucose, 130 mM NaCl, pH7.4) 
before incubating at room temperature in 400 µl uridine uptake buffer containing 
either DMSO (0.1% v/v), NBMPR (100 nM), 8CPT-cAMP (100 µM), 8CPT-2MeO-
cAMP (100 µM), db-cAMP (100 µM) or glucagon (100 nM). After 15 minutes, 400 µl 
uridine uptake buffer containing compounds plus 0.1 µM (2 µCi/ml) 3H-uridine was 
added. After 1 minute, uridine transport was stopped by washing cells five times in 
ice cold uridine uptake buffer containing cold uridine (1 mM). Cells were lysed in 200 
µl 10% (w/v) SDS before scraping.  The amount of uridine taken into the cell was 
determined by scintillation counting. Data is represented as percentage uptake 
compared with untreated control. 
 
Liquid Chromatography – Mass Spectrometry (LC-MS) analysis 
Samples of culture media were transferred into 300 µl micro-vials and capped (PN 
60180-507 and PN 60180-516; Thermo Scientific, Hemel Hempstead, UK). LC-MS 
analysis was performed with a Thermo Accela 600 HPLC system coupled with an 
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Accela PDA detector (Thermo-Fisher Ltd. Hemel Hempstead, UK). The samples 
were stored in the autosampler at 6 °C and analysed within 24 h of preparation. The 
HPLC flow rate was 300 µL/min and the column (Gemini C6-Phenol 110Ä, 150 x 2 
mm, 5 µm particle size; Phenomenex Ltd. Macclesfield, U.K.) was maintained at a 
temperature of 30 ºC. Solvent A was 5 mM ammonium acetate in deionised water 
(ELGA-PureLab option-Q, Elga Ltd, High Wycombe U.K.) adjusted to pH 3.5 with 
acetic acid and solvent B was HPLC grade acetonitrile (Fisher Scientific Ltd, 
Loughborough, UK). Prior to sample analysis, the column was conditioned with 
solvents A and B for 40 min. Samples (10 µL) were injected and eluted on a gradient 
programme of 100% A from 0-2 min, 100 - 95% A  over 2-5 min, 95 - 55% A from 5 - 
25 min, 55% A - 100% B over 25 - 26 min, hold 100% B over 26-29 min, then 100% 
B – 100% A over 29-30 min, hold 100% A from 30-35 min. HPLC needle washes 
were performed with 8:2 acetonitrile:water. The Accela PDA detector collected 
spectra from 200-600 nm and monitored channels at 280, 365 and 520 nm.  
The PDA detector eluent was next transferred to a Thermo LTQ-Orbitrap XL mass 
spectrometry system operated under Xcalibur software (Thermo-Fisher Ltd). For the 
first 3 minutes, the HPLC eluent flow was directed to waste, then from 3 to 35 min to 
the FT-MS detector. Mass spectra were collected in full scan mode (m/z 80-2000) at 
a mass resolution of 30,000 in both positive and negative ESI modes, although 
positive mode provided the greatest sensitivity for AICAR. A second method was 
employed to validate compound identification through retention time and MS2 
spectral matching to the reference standard. Here, data-dependent MS2 CID 
fragmentation spectra (Acquisition-Q 0.25, Activation time 25ms, Normalised 
Collision Energy 10 - optimised for AICAR and metformin) were collected in the LTQ 
for the three most intense ions as defined within the preliminary full FT-MS scan.  
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Both scan events generated 'centroid' spectral data. Scan speeds of 0.1 seconds 
and 0.4 seconds were applied in the LTQ and FT-MS respectively. The Automatic 
Gain Control was set to 1x105 and 5x105 for the LTQ and FT-MS respectively. The 
ESI settings were optimised to allow efficient ionisation and ion transmission with low 
in-source fragmentation; spray voltage +4.5kV; sheath gas 60; auxiliary gas 20; 
capillary voltage +10V; tube lens voltage +80V and capillary temperature at 280ºC.  
The MS detector was calibrated according to the manufacturer’s instructions then 
tuned to optimise detection of ions in the mid m/z 80-2000 range. All samples were 
run in a randomised order, with control and blank samples interspersed every 6 
analyses and at the start and end of the run to monitor the HPLC-MS background 
and target compound carryover.  
A stock solution of 750 µM AICAR (99%+ pure; Sigma Chemical Co. Ltd) was 
prepared in fresh culture media (Dulbecco’s Modified Eagle Medium 1X, Gibco Life 
Technologies Corp., Paisley, UK), then serially diluted in culture media to provide 
calibration standard curves. Extracted ion chromatograms for AICAR were generated 
within the Xcalibur Qual Browser software, peak areas were extracted applying the 
GENESIS peak detection algorithm and the raw extracted peak areas were 
transferred to Microsoft Excel. 
 
Statistics 
All statistical analysis was performed using GraphPad Prism version 6.0.  Mean 
glucose values were taken from each experiment and in one experiment normalised 
to control, which was set at 100% to account for variability between different 
hepatocyte preparations. HGP and western blotting data were analysed by ANOVA.  
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For the Uridine uptake assay, data was expressed as percentage of control uptake 
and analysed by one sample t-test with control set to 100%.   
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Results 
8CPT-cAMP inhibits AICAR but not metformin repression of HGP. 
Primary mouse hepatocytes were serum starved overnight before incubating with 
8CPT-cAMP (100 µM) in the presence or absence of AICAR (250 µM) or metformin 
(250 µM) for 8 hours. Consistent with previous work (26), incubation of hepatocytes 
with 8CPT-cAMP increased HGP. AICAR (250 µM) caused an almost complete 
inhibition of basal but not 8CPT-cAMP-stimulated HGP suggesting that 8CPT-cAMP 
interferes with the ability of AICAR to inhibit HGP. In contrast, even though 
metformin (250 µM) caused only a modest repression of basal HGP, it significantly 
repressed 8CPT-cAMP stimulated HGP (Fig. 1A). Metformin and AICAR both 
activate AMPK. Previous work, including experiments where AMPK activity was 
genetically ablated, indicate that AMPK is not essential for regulation of HGP, even 
though both drugs activate AMPK (13-15; 17; 18). In the current study we used 
AMPK activation purely as a marker of drug entry into the cell. 8CPT-cAMP 
prevented increases in phosphorylation of acetyl CoA carboxylase (ACC) and AMPK 
by AICAR but not metformin (Fig. 1B-D) indicating that activation of the AMPK 
signalling pathway by AICAR was selectively blocked by 8CPT-cAMP.   
 
Inhibition of AICAR’s effects depends on the 8CPT moiety of 8CPT-cAMP. 
We investigated the ability of AICAR to suppress HGP in the presence of db-cAMP 
and glucagon to induce endogenous cAMP. In contrast to 8CPT-cAMP, AICAR 
significantly repressed HGP in the presence of db-cAMP (100 µM; Fig. 2A) and 
glucagon (100 nM; Fig. 2B). In addition, effects of AICAR on AMPK and ACC 
phosphorylation were not modified by db-cAMP and glucagon, (Fig. 2C-E). AICAR 
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also suppressed HGP induced by the adenylate cyclase activator forskolin (100 µM, 
supporting material Fig. 1). 
To determine whether other 8CPT-modified cAMP analogues inhibit the effect of 
AICAR on HGP and AMPK signalling, we utilised 8CPT-2MeO-cAMP. We incubated 
primary mouse hepatocytes with 8CPT-2MeO-cAMP and found that similarly to 8-
CPT-cAMP, 8CPT-2MeO-cAMP blocked repression of HGP by AICAR (Fig. 3A).   
When the effects of 8CPT-2MeO-cAMP on AMPK and ACC phosphorylation were 
studied, we found that like 8CPT-cAMP, 8CPT-2MeO-cAMP selectively inhibited 
AICAR but not metformin’s ability to stimulate AMPK signalling (Fig. 3B-F). 
 
AICAR uptake into hepatocytes is mediated by equilibrative nucleoside 
transporter 1 (ENT1). 
Previous studies have shown that 8-CPT modified cAMP analogues are potent 
inhibitors of the equilibrative nucleoside transporter 1 (ENT1) (23), which in brain 
slices was previously found to mediate AICAR uptake (27). This led us to test 
whether AICAR uptake into hepatocytes may be blocked by inhibition of ENT1. We 
incubated primary mouse hepatocytes with AICAR and metformin in the presence of 
the selective ENT1 inhibitor NBMPR (Fig. 4A). This compound was sufficient to 
promote HGP alone but completely blocked the action of AICAR on HGP (Fig. 4B). 
The effect of metformin on AMPK and ACC phosphorylation was not modified by the 
presence of NBMPR (Fig. 4B-D), whereas AICAR failed to alter AMPK or ACC 
phosphorylation in the presence of NBMPR (Fig. 4B, E, F). These data strongly 
suggest that AICAR uptake into mouse hepatocytes is mediated by ENT1. To 
confirm that 8CPT-cAMP and 8CPT-2MeO-cAMP inhibit ENT1 in hepatocytes, we 
performed an uptake assay using radiolabelled uridine as a tracer and a known 
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ENT1 substrate, to measure ENT1 activity in the absence and presence of NBMPR, 
8CPT-cAMP, 8CPT-2MeO-cAMP, db-cAMP and glucagon. We found that 3H-uridine 
uptake was inhibited by NBMPR, 8CPT-cAMP and 8CPT-2MeO-cAMP but not by 
db-cAMP or glucagon (Fig. 5). To reinforce these findings, we carried out LC-MS 
analysis of AICAR depletion from cellular medium. A scan of the cell culture medium 
without AICAR is presented in Supplementary Fig 2A. On the same column, AICAR, 
ran as a single peak at 2.91 minutes (Supplementary Fig 2B-D). We then established 
that AICAR added to the medium alone was stable up to 24 hours, with LC-MS 
traces superimposable (Fig 5B; 0 minutes versus 360 mins), indicating that AICAR is 
not degraded over this time-period. When compared with media harvested from cells 
treated with AICAR, we observed AICAR loss from the medium (Fig. 5C), which was 
blocked by NBMPR, 8CPT-cAMP and 2MeO-8CPT-cAMP (Fig. 5D).  
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Discussion 
Regulating HGP is key to maintaining adequate blood glucose control in T1 and T2 
diabetes.  Glucagon and a number of cAMP analogues including 8CPT-cAMP and 
db-cAMP are used in pre-clinical studies to mimic HGP in the fasted state, allowing 
liver specific effects of metformin and AICAR on HGP to be studied in vitro.   
This study was initiated by our observation that 8CPT-cAMP selectively blocks 
suppression of HGP and activation of AMPK signalling in response to AICAR but not 
metformin. Db-cAMP and glucagon stimulated HGP, which was reversed by AICAR. 
A second 8CPT-modified analogue, 8CPT-2MeO-cAMP produced a similar selective 
block of the effect of AICAR on both HGP and AMPK signalling. Earlier 
investigations found that 8CPT-cAMP and 8CPT-adenosine did not inhibit the 
binding of [3H]NBMPR to PC12 cells (23) and consequently the mechanism of 8CPT-
cAMP/8CPT-adenosine dependent inhibition of ENT1 is uncertain but likely to be 
related to 8CPT-cAMP being greater than one order of magnitude more lipophilic 
than cAMP (28). This significant off-target effect of 8CPT-modified cAMP analogues 
suggests that caution should be exercised in future studies using 8CPT-cAMP to 
stimulate HGP. In the current study however, we exploited this action of 8CPT-
modified cAMP analogues to compare hepatic actions of AICAR and metformin.  
We excluded a role for PKA/Epac activation in the blocking effect of 8CPT-modified 
cAMP analogues on AICAR-dependent suppression of HGP, on the basis that cAMP 
does not affect the inhibitory effect of AICAR on HGP (raised by the physiological 
inducer of cAMP, glucagon and by the adenylate cyclase activator forskolin). 
Importantly, it has previously been reported that 8CPT-modified cAMP analogues 
inhibit nucleoside transporters (23), which are divided into two different families; 
constitutive nucleoside transporters - CNT (SLC28) of which there are 3 members 
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(CNT1-3) or equilibrative nucleoside transporters ENT (SLC29) of which there are 4 
members (ENT1-4, (29)). These nucleoside transporters are responsible for 
transporting nucleosides such as adenosine and uridine into the cell. In the brain, 
AICAR elevates adenosine levels, thought to be mediated by competition for or 
blockade of ENT1 (27). Therefore we used a highly selective inhibitor of ENT1, 
NBMPR, to demonstrate that ENT1 inhibition is sufficient to block the effect of 
AICAR on HGP and AMPK signalling. Molecular docking data is unavailable for 
8CPT-cAMP analogues docking to ENT1 but in contrast, robust 3D-Quantitative 
Structure-Activity Relationship analysis is available for NBMPR/ENT1 interaction (30-
32). NBMPR did not alter effects of metformin on AMPK and HGP. At the nanomolar 
concentrations used in the current study, NBMPR is highly specific for ENT1, which 
contains a unique high-affinity binding site for this drug (24). In recombinant systems, 
NBMPR inhibits ENT1 7000 fold more potently than ENT2 (24; 33) and it does not 
inhibit CNT3 (34). In rat hepatic membrane preparations, NBMPR is without effect on 
Na+-dependent (concentrative) adenosine transport activity (35). To further validate 
that AICAR was taken up via ENT1, we used 3H-uridine as a tracer. We confirmed 
that 8CPT-cAMP analogues and NBMPR inhibit uridine uptake into hepatocytes. We 
then cross-validated with LC-MS, demonstrating that AICAR is depleted from media 
harvested from AICAR-treated hepatocytes, which was prevented by NBMPR and 
8CPT-modified cAMP analogues. As an additional control, we did not observe any 
major degradation products of AICAR in the medium, indicating that AICAR depletion 
is most likely due to cellular uptake. The difference between AICAR and metformin 
sensitivity to NBMPR is consistent with metformin being taken into the cell via OCT 
transporters as reported previously (19; 20). Our findings may explain previous 
observations that required the use of very high (2 mM) concentrations of AICAR to 
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inhibit 8CPT-cAMP induced HGP (11). Taken together our data suggest that 8CPT-
modified cAMP analogues and NBMPR inhibit ENT1 to block AICAR entry, 
preventing AICAR-mediated inhibition of HGP and activation of AMPK (Fig 5E).  
Direct ENT1 inhibition with NBMPR, which in other tissues raises extracellular 
adenosine levels (36; 37), was sufficient to increase HGP (Fig. 5E). This is likely 
mediated indirectly by activation of adenosine receptor-mediated glycogenolysis or 
gluconeogenesis (38). In addition to adenosine, ENT1 also transports uridine, which 
promotes feeding via activation of hypothalamic uridine diphosphate receptor, P2Y6 
(39) and which may also contribute AMPK-independent effects of AICAR on 
metabolism. Several clinically used drugs inhibit ENT1 as a secondary mode of 
action, including rosuvastatin (40) and dipyridamole (41). Interestingly, rosuvastatin 
increases HbA1c in people with and without diabetes (42) and dipyridamole 
increases glycaemia in mice (43). Taken together, these data suggest that 
therapeutic alterations in purine salvage may produce a clinically significant 
alteration in HGP via modulation of adenosine receptors.  
In summary, we report for the first time that suppression of ENT1 induces HGP. 
ENT1 inhibition also impedes uptake and effects of AICAR but not metformin on 
HGP. These data delineate differing pathways used by AICAR and metformin to 
regulate HGP and more study is required to determine whether exploitation of these 
pathways can be used for therapeutic intervention in diabetes. 
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Figure Legends 
Figure 1 – 8CPT-cAMP inhibits the ability of AICAR but not metformin to 
suppress HGP in primary hepatocytes.  (A) HGP was measured from primary 
mouse hepatocytes after 8 hours incubation with or without 8CPT-cAMP (100 µM) in 
the presence or absence of metformin (Met; 250 µM) or AICAR (250 µM).  (B)  
Representative immunoblots of pThr172 AMPK and pSer79 ACC from primary 
hepatocytes treated with metformin (250 µM), AICAR (250 µM) ± 8CPT-cAMP (100 
µM).  (C, D) provides densitometric analysis of phosphorylation of ACC (C) and 
AMPK (D), expressed as fold change of control (n=3).  All data is expressed as 
mean +/- SEM and analysed by ANOVA (*p<0.05, ** p<0.01, *** p<0.001). Con = 
control in this and all other figures. 
Figure 2 – Dibutyryl cAMP and glucagon do not inhibit the effect of AICAR on 
HGP or AMPK signalling.  Primary mouse hepatocytes were incubated for 8 hours 
with either dibutyryl cAMP (db-cAMP; 100 µM) (A) or glucagon (100 nM) (B) in the 
presence or absence of metformin (Met; 250 µM) or AICAR (250 µM).  The amount 
of glucose produced was measured as in Fig. 1A. (C) Immunoblots showing pT172 
AMPK and pS79 ACC phosphorylation in response to db-cAMP (100 µM). (D, E) 
provides densitometric analysis of phosphorylation of ACC (D) and AMPK (E), 
expressed as fold change of control.  Data is expressed as mean +/- SEM from three 
separate experiments and analysed by ANOVA (*p<0.05, ** p<0.01, *** p<0.001 in 
pairwise differences).  
Figure 3 – Suppression of HGP and AMPK signalling by AICAR is inhibited by 
the 8CPT-modified cAMP analogue 8CPT-2-Methyl-O-cAMP.  Primary 
hepatocytes were treated for 8 hours with metformin (Met; 250 µM) or AICAR (250 
µM) ± 8CPT-2MeO-cAMP (100 µM) (A).  Media was harvested and HGP measured 
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as in Fig. 1 A (n=4).  (B) Representative immunoblots of pThr172 AMPK and pSer79 
ACC phosphorylation in lysates treated with metformin (Met; 250 µM) or AICAR (250 
µM) ± 8CPT-2MeO-cAMP (100 µM). (C-F) provides densitometric analysis of ACC 
(C, E) and AMPK (D, F) phosphorylation, expressed as fold change of control (n=4). 
Data is expressed as mean +/- SEM and analysed by ANOVA (*p<0.05, ** p<0.01, 
*** p<0.001 in pairwise comparisons). 
Figure 4 - AICAR uptake into hepatocytes is mediated by equilibrative 
nucleoside transporter 1 (ENT1).  (A) HGP was measured after incubation for 8 
hours with the selective ENT1 inhibitor NBMPR (100 nM) ± metformin (250 µM) or 
AICAR (250 µM).  The amount of glucose produced was normalised to protein 
content and expressed as % control. (B) Representative immunoblots measuring 
pThr172 AMPK and pSer79 ACC by metformin (250 µM) or AICAR (250 µM) ± 
NBMPR (100 nM). (C-F) provides densitometric analysis of ACC (C, E) and AMPK 
(D, F) phosphorylation, expressed as fold change of control.  Data is taken from 4 
separate experiments and shown as mean +/- SEM, (*p<0.05 ** p<0.01, *** p<0.001 
in pairwise comparisons, ‘ns’ denotes not significant). 
Figure 5 - Nucleoside transport via equilibrative nucleoside transporter 1 
(ENT1) is inhibited by 8CPT-modified cAMP analogues.  Uridine uptake into 
hepatocytes was measured using 3H-uridine uptake assay.  Hepatocytes were 
incubated for 15 minutes with NBMPR (100 nM), 8CPT-cAMP (100 µM), Dibutyryl 
cAMP (100 µM), glucagon (100 nM) or 8CPT-2MeO-cAMP (100 µM) before 
measuring 3H transport into the cell for one minute.  Data is expressed as mean +/- 
SEM and is represented as % uridine uptake relative to control. (n=3; **p<0.01, *** 
p<0.001; NS denotes not significant). (B) LC-MS analysis of AICAR in medium 
without cells at zero time and 6h incubation. The top two traces show the similarity 
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between total MS signal at zero time and 6h incubation. The bottom two traces show 
the signal at the selected m/z 259 for AICAR and demonstrate that AICAR is 
effectively stable under these conditions. The full-scale deflection of the MS detector 
is given in the top right corner of each trace. (C) AICAR disappearance from medium 
in the presence of primary hepatocytes. AICAR in media was measured by LC-MS 
and expressed as µM AICAR. Data is expressed as mean +/- SEM and analysed by 
ANOVA (*p<0.05 in pairwise comparisons). (D) Effect of NBMPR, 8CPT-cAMP and 
2MeO-8CPT-cAMP on AICAR disappearance from the medium. AICAR in media 
was measured by LC-MS and expressed as peak areas in MS detector units. Data is 
expressed as mean +/- SEM and analysed by ANOVA ((*p<0.05 & ** p<0.01 in 
pairwise comparisons)). 
(E) Schematic representation of AICAR and metformin entry into hepatocytes and 
consequences of equilibrative nucleoside transporter (ENT1) inhibition. Upper 
section: AICAR enters the hepatocyte through ENT1, where it is converted to AICAR 
monophosphate (ZMP), resulting in suppression of HGP through AMPK-independent 
targets. Metformin enters hepatocytes at least in part through organic cationic 
transporters (OCT) and inhibits HGP through mechanisms including mitochondrial 
inhibition affecting adenine nucleotide levels/ratios. Lower section: NBMPR inhibits 
adenosine uptake into hepatocytes through ENT1, raising HGP which is possibly 
mediated, at least in part, by an adenosine receptor (Adora)-mediated process. 
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